Establishment of a first-order kinetic model of light chain-associated amyloid fibril extension in vitro

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1601, Issue 1, 2002, Pages 110-120

  Takahashi, Naoki ^a,b   Hasegawa, Kazuhiro ^a   Yamaguchi, Itaru ^a   Okada, Hiromi ^a   Ueda, Takanori ^a   Gejyo, Fumitake ^b   Naiki, Hironobu ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Amyloid fibril; First order kinetic model; Glycosaminoglycan; Light chain associated amyloidosis; Nordihydroguaiaretic acid; Thioflavin T

Indexed keywords

ALPHA 1 MICROGLOBULIN; AMYLOID; AMYLOID PROTEIN; ANTIOXIDANT; APOLIPOPROTEIN E3; DERMATAN SULFATE; FIBRONECTIN; NORDIHYDROGUAIARETIC ACID; RECOMBINANT PROTEIN; THIOFLAVINE; AMYLOID BETA PROTEIN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTRON MICROSCOPY; FEMALE; FLUOROMETRY; HUMAN; HUMAN TISSUE; MALE; MOLECULAR MECHANICS; MOLECULAR MODEL; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PURIFICATION; CHEMISTRY; KINETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; SPECTROFLUOROMETRY; ULTRASTRUCTURE;

ADULT; AGED; AMYLOID BETA-PROTEIN; AMYLOIDOSIS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; KINETICS; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; SPECTROMETRY, FLUORESCENCE;

EID: 0037137135     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-9639(02)00435-1     Document Type: Article

References (68)

1. Bellotti V., Mangione P., Merlini G. Review: immunoglobulin light chain amyloidosis - the archetype of structural and pathogenic variability. J. Struct. Biol. 130:2000;280-289.
2. Kyle R.A., Gertz M.A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin. Hematol. 32:1995;45-59.
3. Glenner G.G., Ein D., Eanes E.D., Bladen H.A., Terry W., Page D.L. Creation of "amyloid" fibrils from Bence Jones proteins in vitro. Science. 174:1971;712-714.
4. Jarrett J.T., Lansbury P.T. Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 73:1993;1055-1058.
5. Naiki H., Gejyo F. Kinetic analysis of amyloid fibril formation. Methods Enzymol. 309:1999;305-318.
6. Naiki H., Higuchi K., Hosokawa M., Takeda T. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T. Anal. Biochem. 177:1989;244-249.
7. Naiki H., Higuchi K., Nakakuki K., Takeda T. Kinetic analysis of amyloid fibril polymerization in vitro. Lab. Invest. 65:1991;104-110.
8. Naiki H., Nakakuki K. First-order kinetic model of Alzheimer's β-amyloid fibril extension in vitro. Lab. Invest. 74:1996;374-383.
9. Naiki H., Hashimoto N., Suzuki S., Kimura H., Nakakuki K., Gejyo F. Establishment of a kinetic model of dialysis-related amyloid fibril extension in vitro. Amyloid: Int. J. Exp. Clin. Invest. 4:1997;223-232.
10. Stevens F.J., Myatt E.A., Chang C.H., Westholm F.A., Eulitz M., Weiss D.T., Murphy C., Solomon A., Schiffer M. A molecular model for self-assembly of amyloid fibrils: immunoglobulin light chains. Biochemistry. 34:1995;10697-10702.
11. Ionescu-Zanetti C., Khurana R., Gillespie J.R., Petrick J.S., Trabachino L.C., Minert L.J., Carter S.A., Fink A.L. Monitoring the assembly of Ig light-chain amyloid fibrils by atomic force microscopy. Proc. Natl. Acad. Sci. U. S. A. 96:1999;13175-13179.
12. Solomon A., Weiss D.T., Murphy C.L., Hrncic R., Wall J.S., Schell M. Light chain-associated amyloid deposits comprised of a novel κ constant domain. Proc. Natl. Acad. Sci. U. S. A. 95:1998;9547-9551.
13. Wall J., Schell M., Murphy C., Hrncic R., Stevens F.J., Solomon A. Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. Biochemistry. 38:1999;14101-14108.
14. Wall J., Murphy C.L., Solomon A. In vitro immunoglobulin light chain fibrillogenesis. Methods Enzymol. 309:1999;204-217.
15. Kim Y.S., Cape S.P., Chi E., Raffen R., Wilkins-Stevens P., Stevens F.J., Manning M.C., Randolph T.W., Solomon A., Carpenter J.F. Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains. J. Biol. Chem. 276:2001;1626-1633.
16. Khurana R., Gillespie J.R., Talapatra A., Minert L.J., Ionescu-Zanetti C., Millett I., Fink A.L. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. Biochemistry. 40:2001;3525-3535.
17. Hurle M.R., Helms L.R., Li L., Chan W., Wetzel R. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc. Natl. Acad. Sci. U. S. A. 91:1994;5446-5450.
18. Bellotti V., Stoppini M., Mangione P.P., Fornasieri A., Min L., Merlini G., Ferri G. Structural and functional characterization of three human immunoglobulin κ light chains with different pathological implications. Biochim. Biophys. Acta. 1317:1996;161-167.
19. Raffen R., Dieckman L.J., Szpunar M., Wunschl C., Pokkuluri P.R., Dave P., Wilkins-Stevens P., Cai X., Schiffer M., Stevens F.J. Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains. Protein Sci. 8:1999;509-517.
20. Kim Y.S., Wall J.S., Meyer J., Murphy C., Randolph T.W., Manning M.C., Solomon A., Carpenter J.F. Thermodynamic modulation of light chain amyloid fibril formation. J. Biol. Chem. 275:2000;1570-1574.
21. Yamada T., Kakihara T., Gejyo F., Okada M. A monoclonal antibody recognizing apolipoprotein E peptides in systemic amyloid deposits. Ann. Clin. Lab. Sci. 24:1994;243-249.
22. Castaño E.M., Prelli F., Pras M., Frangione B. Apolipoprotein E carboxyl-terminal fragments are complexed to amyloids A and L. Implications for amyloidogenesis and Alzheimer's disease. J. Biol. Chem. 270:1995;17610-17615.
23. Pepys M.B., Dyck R.F., de Beer F.C., Skinner M., Cohen A.S. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin. Exp. Immunol. 38:1979;284-293.
24. Scott D.L., Marhaug G., Husby G. Comparative studies of the high molecular weight amyloid fibril proteins and similar components from normal tissues. Clin. Exp. Immunol. 52:1983;693-701.
25. Westermark G.T., Norling B., Westermark P. Fibronectin and basement membrane components in renal amyloid deposits in patients with primary and secondary amyloidosis. Clin. Exp. Immunol. 86:1991;150-156.
26. Cardoso I., Pereira P.J., Damas A.M., Saraiva M.J. Aprotinin binding to amyloid fibrils. Eur. J. Biochem. 267:2000;2307-2311.
27. Nelson S.R., Lyon M., Gallagher J.T., Johnson E.A., Pepys M.B. Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils. Biochem. J. 275:1991;67-73.
28. Stenstad T., Magnus J.H., Kolset S.O., Cornwell G.G. III, Husby G. Macromolecular properties of glycosaminoglycans in primary AL amyloid fibril extracts of lymphoid tissue origin. Scand. J. Immunol. 34:1991;611-617.
29. Sezer O., Niemoller K., Jakob C., Langelotz C., Eucker J., Possinger K. Novel approaches to the treatment of primary amyloidosis. Expert Opin. Investig. Drugs. 10:2000;2343-2350.
30. Merlini G., Ascari E., Amboldi N., Bellotti V., Arbustini E., Perfetti V., Ferrari M., Zorzoli I., Marinone M.G., Garini P., Diegoli M., Trizio D., Ballinari D. Interaction of the anthracycline 4′-iodo-4′- deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc. Natl. Acad. Sci. U. S. A. 92:1995;2959-2963.
31. Pras M., Schubert M., Zucker-Franklin D., Rimon A., Franklin E.C. The characterization of soluble amyloid prepared in water. J. Clin. Invest. 47:1968;924-933.
32. Yamaguchi I., Hasegawa K., Naiki H., Mitsu T., Matuo Y., Gejyo F. Extension of A β2M amyloid fibrils with recombinant human β2-microglobulin. Amyloid: J. Protein Folding Disord. 8:2001;30-40.
33. Schägger H., von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal. Biochem. 166:1987;368-379.
34. Yamaguchi I., Hasegawa K., Takahashi N., Gejyo F., Naiki H. Apolipoprotein E inhibits the depolymerization of β2-microglobulin-related amyloid fibrils at a neutral pH. Biochemistry. 40:2001;8499-8507.
35. Abraham C.R., Selkoe D.J., Potter H. Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell. 52:1988;487-501.
36. Argiles A., Mourad G., Axelrud-Cavadore C., Watrin A., Mion C., Cavadore J.C. High-molecular-mass proteins in haemodialysis-associated amyloidosis. Clin. Sci. (Lond). 76:1989;547-552.
37. Naiki H., Gejyo F., Nakakuki K. Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's β-amyloid fibril formation in vitro. Biochemistry. 36:1997;6243-6250.
38. Naiki H., Hasegawa K., Yamaguchi I., Nakamura H., Gejyo F., Nakakuki K. Apolipoprotein E and antioxidants have different mechanisms of inhibiting Alzheimer's β-amyloid fibril formation in vitro. Biochemistry. 37:1998;17882-17889.
39. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
40. Riddles P.W., Blakeley R.L., Zerner B. Reassessment of Ellman's reagent. Methods Enzymol. 91:1983;49-60.
41. Odani S., Komori Y., Gejyo F. Structural analysis of the amyloidogenic κ Bence Jones protein (FUR). Amyloid: Int. J. Exp. Clin. Invest. 6:1999;77-88.
42. Rostagno A., Vidal R., Kaplan B., Chuba J., Kumar A., Elliott J.I., Frangione B., Gallo G., Ghiso J. pH-dependent fibrillogenesis of a VκIII Bence Jones protein. Br. J. Haematol. 107:1999;835-843.
43. Evans K.C., Berger E.P., Cho C.-G., Weisgraber K.H., Lansbury P.T. Jr. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 92:1995;763-767.
44. Pearson W.R., Lipman D.J. Improved tools for biological sequence comparison. Proc. Natl. Acad. Sci. U. S. A. 85:1988;2444-2448.
45. Dwulet F.E., Strako K., Benson M.D. Amino acid sequence of a lambda VI primary (AL) amyloid protein (WLT). Scand. J. Immunol. 22:1985;653-660.
46. Schormann N., Murrell J.R., Liepnieks J.J., Benson M.D. Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation. Proc. Natl. Acad. Sci. U. S. A. 92:1995;9490-9494.
47. Linke R.P., Zucker-Franklin D., Franklin E.C. Morphologic, chemical, and immunologic studies of amyloid-like fibrils formed from Bence Jones proteins by proteolysis. J. Immunol. 111:1973;10-23.
48. Olsen K.E., Sletten K., Westermark P. Fragments of the constant region of immunoglobulin light chains are constituents of AL-amyloid proteins. Biochem. Biophys. Res. Commun. 251:1998;642-647.
49. Röcken C., Hegenbarth V., Schmitz M., Stix B., Schade G., Mohnert A., Roessner A. Plasmacytoma of the tonsil with AL amyloidosis: evidence of post-fibrillogenic proteolysis of the fibril protein. Virchows Arch. 436:2000;336-344.
50. Shirahama T., Benson M.D., Cohen A.S., Tanaka A. Fibrillar assemblage of variable segments of immunoglobulin light chains: an electron microscopic study. J. Immunol. 110:1973;21-30.
51. Wisniewski T., Castaño E.M., Golabek A., Vogel T., Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145:1994;1030-1035.
52. Ma J., Yee A., Brewer H.B. Jr., Das S., Potter H. Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature. 372:1994;92-94.
53. Castillo G.M., Lukito W., Wight T.N., Snow A.D. The sulfate moieties of glycosaminoglycans are critical for the enhancement of β-amyloid protein fibril formation. J. Neurochem. 72:1999;1681-1687.
54. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240:1988;622-630.
55. McLaurin J., Yang D.-S., Yip C.M., Fraser P.E. Review: modulating factors in amyloid-β fibril formation. J. Struct. Biol. 130:2000;259-270.
56. Hynes R.O. Fibronectins. Sci. Am. 254:1986;42-51.
57. Lyon A.W., Narindrasorasak S., Young I.D., Anastassiades T., Couchman J.R., McCarthy K.J., Kisilevsky R. Co-deposition of basement membrane components during the induction of murine splenic AA amyloid. Lab. Invest. 64:1991;785-790.
58. Snow A.D., Willmer J.P., Kisilevsky R. Sulfated glycosaminoglycans in Alzheimer's disease. Human Pathol. 18:1987;506-510.
59. Ohishi H., Skinner M., Sato-Araki N., Okuyama T., Gejyo F., Kimura A., Cohen A.S., Schmid K. Glycosaminoglycans of the hemodialysis-associated carpal synovial amyloid and of amyloid-rich tissues and fibrils of heart, liver, and spleen. Clin. Chem. 36:1990;88-91.
60. Stenstad T., Magnus J.H., Kolset S.O., Husby G. Identification of glycosaminoglycans in human renal and splenic secondary AA amyloid fibril preparations. Scand. J. Rheumatol. 20:1991;1-7.
61. Jiang X., Myatt E., Lykos P., Stevens F.J. Interaction between glycosaminoglycans and immunoglobulin light chains. Biochemistry. 36:1997;13187-13194.
62. Castillo G.M., Cummings J.A., Yang W., Judge M.E., Sheardown M.J., Rimvall K., Hansen J.B., Snow A.D. Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. Diabetes. 47:1998;612-620.
63. Findeis M.A. Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization. Biochim. Biophys. Acta. 1502:2000;76-84.
64. Kisilevsky R., Lemieux L.J., Fraser P.E., Kong X., Hultin P.G., Szarek W.A. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat. Med. 1:1995;143-148.
65. Gianni L., Bellotti V., Gianni A.M., Merlini G. New drug therapy of amyloidoses: resorption of AL-type deposits with 4′-iodo-4′- deoxydoxorubicin. Blood. 86:1995;855-861.
66. Merlini G., Anesi E., Garini P., Perfetti V., Obici L., Ascari E., Lechuga M.J., Capri G., Gianni L. Treatment of AL amyloidosis with 4′-lodo-4′-deoxydoxorubicin: an update. Blood. 93:1999;1112-1113.
67. Goodman Y., Steiner M.R., Steiner S.M., Mattson M.P. Nordihydroguaiaretic acid protects hippocampal neurons against amyloid β-peptide toxicity, and attenuates free radical and calcium accumulation. Brain Res. 654:1994;171-176.
68. Fagarasan M.O., Efthimiopoulos S. Mechanism of amyloid β-peptide (1-42) toxicity in PC12 cells. Mol. Psychiatry. 1:1996;398-403.